TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: iCBT for Long-term Conditions in IAPT

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age~* English language speakers~* Have capacity to consent~* Has a chronic condition (Diabetes, COPD, Chronic Pain) with comorbid depression and/or anxiety.~* Suitable for step 2 intervention in NHS IAPT Services.~Exclusion Criteria:~* Exceed cut-off score for risk in terms of self-harm on the screening questionnaires.~* Receiving an intervention (therapeutic or biological) that is not a part of treatment as usual, or another trial.

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Space in Diabetes (Type: EXPERIMENTAL): The SilverCloud interventions comprise of 8 modules of evidence-based CBT which have been tailored. Psychoeducational content in the diabetes programme focusses on the impact that mood can have on self-management and self-care when living with diabetes.
- Space in COPD (Type: EXPERIMENTAL): The SilverCloud interventions comprise of 8 modules of evidence-based CBT which have been tailored. Additional content on panic has been included in the COPD programme. Symptoms of COPD and anxiety can be closely linked, and this content provides CBT-based strategies for dealing with symptoms of panic and anxiety.
- Space in Chronic Pain (Type: EXPERIMENTAL): The SilverCloud interventions comprise of 8 modules of evidence-based CBT which have been tailored. A module on health anxiety, titled Anxiety and your Health, has been added to the chronic pain programme. This module provides psychoeducational content on health anxiety, the unhelpful behaviours that accompany it and how these can negatively impact on the experience of pain.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: BLood Groups as Biomarker to Optimize Odds of Response to Anti-PD-1 Drugs

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven advanced melanoma.~* Anti-PD-1 monotherapy of advanced (unresectable or metastatic) melanoma (prescribed within its approved indication as per usual practice according to RIZIV/INAMI regulations) in the first-line setting.~* No prior systemic therapy for advanced melanoma.~* Have measurable disease per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1.~* At least 18 years of age.~Exclusion Criteria:~* Prior treatment with any drug specifically targeting T-cell co-stimulation or immune checkpoints (e.g., antibodies targeting PD-(L)1 or CTLA-4, chimeric antigen receptor T (CAR-T) cell therapy).~* Metastasis-directed therapy (surgery or radiotherapy) with definitive intent (local therapy to address symptomatic sites of disease is permitted).~* Previous systemic treatment for advanced melanoma.~* Active central nervous system (CNS) metastases (previously treated brain metastases are permitted if stable) or carcinomatous meningitis.~* Diagnosis of any other malignancy within 5 years prior to study inclusion, except for adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the breast or of the cervix, low-risk prostate cancer on surveillance without any plans for treatment intervention, or prostate cancer that has been adequately treated with prostatectomy or radiotherapy and currently with no evidence of disease and symptoms.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients with advanced melanoma (Type: None): Patients receiving anti-PD-1 monotherapy (Nivolumab or Pembrolizumab) in the first-line setting

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Anti-pneumococcal Vaccine Strategy in Patients Treated With Immunosuppressants or Biotherapies for CIBD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient who have given their written consent in a free and informed consent~* Patient followed for inflammatory bowel disease (Crohn's disease, ulcerative colitis or indeterminate colitis), and treated for at least 3 months by immunosuppressive therapy and /or biotherapies and in clinical remission for at least 3 months~* Patient agreeing to participate in the study throughout its duration and accepting the procedures related to the study~* Contraception that the investigator judges effective for the first 12 months of the trial, with a negative pregnancy test~* Women not planning to become pregnant in the 12 months following inclusion (M0)~* Patient with social coverage~Exclusion Criteria:~* Patients vaccinated against pneumo23 for less than 5 years~* Other vaccination during the month before inclusion~* Patient develops a febrile illness (at least 37 ° C 5 measured orally) or acute infection in the week before vaccination~* The patient has a flare up of IBD the day of vaccination (Harvey-Brasdshaw score of at least 6 or CDAI \> 220 for Crohn's disease or Mayo Clinic score of at least 4 for UC and indeterminate colitis)~* Patients with an ongoing pregnancy the day of vaccination~* Patient with a known history of neuropathy as Guillain-Barré syndrome.~* Patients with known infection with HIV and / or HBV (HBsAg positive) and / or HCV~* Patient with other severe immune deficiency~* Patients who received immunoglobulin infusions of blood products, or of monoclonal antibodies (except anti-TNF) in the 3 months prior to vaccination~* Patient institutionalized, or deprived of liberty administrative or judicial~* Patients treated without immunosuppressive therapy or biotherapies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 dose Prevenar13 and 1 dose PSV23 (Type: ACTIVE_COMPARATOR): one dose of the polysaccharide vaccine, Prevenar 13 at M0 and one dose of polysaccharide vaccine, Pneumo 23 at M4
- 2 doses Prevenar13 and 1 dose PSV23 (Type: EXPERIMENTAL): one dose of the polysaccharide vaccine, Prevenar 13 at M0, one dose of the polysaccharide vaccine, Prevenar 13, at M2 and one dose of polysaccharide vaccine, Pneumo 23 at M4

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Platelet-rich Plasma vs. Whole Blood for Gluteus Medius Tendinopathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Moderate to severe lateral hip pain for greater than 3 months~* Symptoms are refractory to conservative treatment, including at least 8 weeks of traditional physical therapy for this condition~* Moderate to severe gluteus medius tendinosis with or without partial tear \<1 cm~* Normal neurologic exam except for hip abductor weakness on the affected side~Exclusion Criteria:~* Severe (Tonnis grade \>1) hip osteoarthritis with active synovitis or bone edema~* Active lumbar radiculopathy with pain, numbness or weakness in a dermatomal distribution~* No evidence of fatty atrophy, denervation, or complete tears of gluteus medius seen on MRI~* Any condition that requires anti-platelet or anti-coagulation therapy, including aspirin therapy for cardiac conditions~* Non-English speaking

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- PRP (Type: EXPERIMENTAL): None
- Whole Blood (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Follicular and Blood G-CSF During a Natural Cycle of IVF

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Women between 18 and 43 years old~* Women natural In Vitro Fecondation~Exclusion Criteria:~* No exclusion criteria

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 43 Years
- Healthy Volunteers: f

Study Arms:
- G-CSF FIV nat (Type: None): Patient following a natural In Vitro Fecondation cycle

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pennsylvania Adolescent Intervention Research Study (PAIRStudy)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 12 to 17 years of age~* HAM-D score of \> 14~* Meet diagnostic criteria for either Major Depressive Disorder, Dysthymia, or Depression NOS~* Have a parent or guardian willing to participate~Exclusion Criteria:~* Currently Suicidal~* History of mental retardation or borderline intellectual functioning~* Current psychosis~* Primary caregiver unwilling to participate

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 18 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Substudy of Change in Cardiometabolic Disease (CMD) Risk Factors During an Interactive Fitness Program

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Participation in main intervention study~Exclusion Criteria:~* Unwillingness to comply with study requirements including two visits and data collection procedures

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 12 Years
- Healthy Volunteers: t

Study Arms:
- Physical Activity and Nutrition (Type: None): Supervised physical activity in the form of novel gaming and exercise equipment several times per week for 12 weeks will be provided in addition to weekly nutrition education sessions.
- Nutrition Education Only (Type: None): Children in this group will receive weekly group nutrition sessions, identical to those provided for the Physical Activity + Nutrition group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Quadratus Lumborum Block vs Transversus Abdominis Plane Block for Post-prostatectomy Analgesia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pateints who will have prostatectomy ASA II or III~Exclusion Criteria: Patient refusal Local infection at the site of injection Allergy to study medications Sepsis Anatomic abnormalities Systemic anticoagulation or coagulopathy Inability to comprehend or participate in pain scoring system Inability to use intravenous patient controlled analgesia~-

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Quadratus Lumborum block group (Type: EXPERIMENTAL): Quadratus Lumborum block group (QL) patients will receive a bilateral Quadratus Lumborum block using Bupivicaine 0.125%
- Transversus abdominis plane block group (Type: EXPERIMENTAL): Transversus abdominis plane block (TAP) patients will receive a bilateral TAP block using Bupivicaine 0.125%

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Nitric Oxide Generating Gel Dressing in Patients With Superficial Partial Thickness Wounds

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who have a Superficial Partial Thickness wound (2a) either from a thermal injury or from a skin graft donor site under the care of St. Andrews service, within the recruitment timeline.~* Wound area to be treated in study must be less than 5% of total body surface area (TBSA).~* Patients aged over 12 months and up to and including 80 years old.~* Informed Consent~Exclusion Criteria:~* Any inclusion criteria not met~* Unwilling to consent to investigation/ unable to provide consent~* Wounds deeper than superficial partial thickness (2b, 3 and 4)~* Chemical /Electrical burns~* Already having received silver sulfadiazine~* Disease that could affect wound healing~* Previous participation in the study~* Females who are pregnant or breast-feeding.~* Relative, spouse or employee of the investigational site~* Known multiple allergic disorders~* Skin disorders~* Facial burns~* Patients who have taken part in any investigational studies within the last 30 days prior to participation.

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SPT Burn Wound (Type: OTHER): Each wound will be divided into 2 with half the wound being treated with the NOx dressing and the other half with standard of care
- SPT graft donor site (Type: OTHER): Each wound will be divided into 2 with half the wound being treated with the NOx dressing and the other half with standard of care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Botulinum Toxin on Muscle and Brain Activity

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Subject inclusion criteria:~* Diagnosis: PCD~* Receiving BoNT at the University of Florida (UF)~Subject exclusion criteria:~* Secondary torticollis~* Pregnancy~* Active seizure disorder~* Presence of metallic body such as pacemaker, implants, metal rods and hearing aid~Control inclusion criteria:~* Age 21-80 years~Control exclusion criteria:~* Any form of torticollis~* Pregnancy~* Active seizure disorder~* Presence of metallic body such as pacemaker, implants, metal rods and hearing aid

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- Cervical Dystonia (Type: EXPERIMENTAL): 'Botulinum Toxin injection' will be done and 'physiological measures' will then be collected.
- Healthy controls (Type: OTHER): No Botulinum toxin is injected, 'physiological measures' will be collected as a healthy comparator.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Melatonin Studies of Totally Blind Children

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Totally blind~* Between 5-8 yrs or 17-20 yrs of age~Exclusion Criteria:~* Pregnancy~* Light perception~* Low melatonin production~* Taking melatonin~* Co-morbid medical disorders (such as seizure disorders)

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 20 Years
- Healthy Volunteers: t

Study Arms:
- Observational (Type: NO_INTERVENTION): Observe to determine free-running versus entrained status.
- Melatonin (Type: EXPERIMENTAL): Subjects with free-running rhythms will take melatonin.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: CD34+ Stem Cell Infusion to Augment Graft Function

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~To be eligible for this protocol, patients must have the following:~1. Primary immunodeficiency (e.g. SCID, Wiskott-Aldrich and/or other more rare conditions and other bone marrow failure syndromes) with prior allogeneic stem cell transplant.~2. Waning donor chimerism or immune function that is inadequate to correct their disease or clinical condition, for which primary transplant was given, as determined by their attending physician.~3. Available primary donor.~4. Must not have other organ dysfunction deemed by the attending physician to preclude this procedure.~5. Age \< 35 years at time of transplant~6. One of the following must be true:~   * Patients must have evidence of persistent or recurrent immunodeficiency or thrombocytopenia.~-OR-~• Primary immunodeficiency disease with known potential to progress to malignant condition if untreated.~-OR-~• Debilitating secondary disease known to be a consequence of inadequate immune response to known agent or pathogen, uncontrollable by other available medical therapies (e.g. third patient described on page 5).~Exclusion Criteria:~1. Absence of an available original donor~2. Failure to sign consent form, or inability to undergo informed consent process~3. Pregnant or lactating female~4. Uncontrolled GVHD

- Gender: ALL
- Minimum Age: None
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- CD34+ selected stem cell infusion (Type: EXPERIMENTAL): An infusion of selected CD34+ stem cells will be given without any preparative regimen.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Tracking and Exploring the Source of Viral REbound

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* - Age\>18year old~* Nadir CD4\>200/mm3~* CD4/CD8 ratio\> 0.5~* Continuous antiretroviral therapy for more than 2 years~* Plasma Human Immunodeficiency Virus (HIV) 1 Ribonucleic acid (RNA) \<50 copies/ml in the last 2 years~* Viral Load (VL)\<20copies at inclusion~* Patients who are willing to participate and who understand the trial (particularly, the obligation to have protected intercourse during the study).~* Informed consent~* Short half-life treatment~* Health insurance~* A subset of CD4 (T4cells) express CD32a.~Exclusion Criteria:~* - Acquired Immune Deficiency Syndom (AIDS)~* Pregnancy~* Human immunodeficiency virus (HIV)-2 co infection~* Thrombopenia~* Neurological events during primary infection~* Hepatitis B + (HBV+)~* Hepatitis C + (HCV+)~* Cancer during the last 5 years.~* Life expectancy \< 12 months~* Autoimmunity~* Acute infectious disease in the last 60 days.~* Hemoglobin\<7g/dl~* Glomerular filtration \< 60ml/min~* Refusing protected intercourse~* Risk of HIV transmission~* Psychiatric disorders.~* Alcool and drug abuse~* Involvement in another clinical trial evaluating a therapeutic.~* Being under tutorship~* Being deprived of liberty

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Antiretroviral therapy (Type: EXPERIMENTAL): Stopping antiretroviral therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Acupuncture on Symptoms of Diarrhea and Pain in IBS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* frequence of bowel movement of at least 3/day~* global disease severity of at least 3~Exclusion Criteria:~* taking medications which will influence frequency of bowel movement~* patient taking anticoagulants or suffering from coagulopathy~* pregancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: AutoPulse Assisted Prehospital International Resuscitation Trial (ASPIRE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All persons with out-of-hospital cardiac arrest who are attended by a vehicle involved in the randomization process and who are treated by the emergency medical service (EMS).~Exclusion Criteria:~* Persons under the age of 18~* Victims with traumatic arrest~* Less than the legal age of consent~* Resuscitation attempt discontinued because of do not resuscitate (DNR) orders or on request of authorized decision-maker~* Wards of the state, including prisoners~* Chest or abdominal surgery within 6 weeks~* Site specific exclusions

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Autopulse device
- 2 (Type: ACTIVE_COMPARATOR): Manual CPR

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy